Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Part of paid clinical trials in New York, New York.

Sponsor: Memorial Sloan Kettering Cancer Center
Study ID: NCT00546377
Phase: PHASE1/PHASE2
Status: Completed

Conditions

Eligibility Criteria

Sex: ALL
Age: 18 Years - 120 Years
Healthy Volunteers: Not accepted

Interventions

filgrastim — BIOLOGICAL
pegfilgrastim — BIOLOGICAL
rituximab — BIOLOGICAL
sargramostim — BIOLOGICAL
cyclophosphamide — DRUG
mitoxantrone hydrochloride — DRUG
pentostatin — DRUG
fluorescence in situ hybridization — GENETIC
gene rearrangement analysis — GENETIC
polymerase chain reaction — GENETIC
protein expression analysis — GENETIC
flow cytometry — OTHER
biopsy — PROCEDURE

Study Details

RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving pentostatin together with combination chemotherapy and rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of mitoxantrone when given together with pentostatin, cyclophosphamide, and rituximab and to see how well it works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell cancer.